Compare PRZO & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PRZO | NEUP |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | Israel | United States |
| Employees | N/A | 8 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 23.0M |
| IPO Year | 2022 | N/A |
| Metric | PRZO | NEUP |
|---|---|---|
| Price | $1.28 | $4.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 562.7K | 38.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $3.65 |
| 52 Week High | $2.15 | $21.31 |
| Indicator | PRZO | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 58.34 |
| Support Level | $1.11 | $3.92 |
| Resistance Level | $1.48 | $4.56 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 70.93 | 52.55 |
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.